Moloney Securities Asset Management LLC Has $297,000 Stock Position in SOPHiA GENETICS SA (NASDAQ:SOPH)

Moloney Securities Asset Management LLC lowered its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 50.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 81,500 shares of the company’s stock after selling 83,500 shares during the quarter. Moloney Securities Asset Management LLC owned approximately 0.12% of SOPHiA GENETICS worth $297,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Green Alpha Advisors LLC acquired a new position in SOPHiA GENETICS during the third quarter worth approximately $79,000. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after buying an additional 23,000 shares during the last quarter. Banque Cantonale Vaudoise increased its position in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after buying an additional 9,000 shares during the last quarter. Principal Financial Group Inc. increased its position in SOPHiA GENETICS by 35.9% during the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after buying an additional 361,201 shares during the last quarter. Finally, Akre Capital Management LLC acquired a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $1,418,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $3.40 on Thursday. SOPHiA GENETICS SA has a 12 month low of $2.70 and a 12 month high of $7.37. The stock’s 50 day moving average is $3.68 and its 200-day moving average is $4.24. The company has a current ratio of 4.40, a quick ratio of 4.17 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $222.29 million, a price-to-earnings ratio of -3.28 and a beta of 1.03.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. The business had revenue of $15.81 million during the quarter, compared to analysts’ expectations of $17.58 million. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 102.84%. During the same period in the previous year, the company posted ($0.33) earnings per share. Equities research analysts expect that SOPHiA GENETICS SA will post -0.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Royal Bank of Canada decreased their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Morgan Stanley downgraded SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $10.00 to $5.00 in a research report on Wednesday, August 7th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.